The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of HRD in patients with pancreatic adenocarcinoma undergoing surgical resection: An updated analysis.
 
Gudbjorg Jonsdottir
No Relationships to Disclose
 
Asgeir Thor Masson
No Relationships to Disclose
 
Laura S. Jacobus
No Relationships to Disclose
 
Michelle L. Churchman
No Relationships to Disclose
 
Stephen B. Edge
Honoraria - North American Center for Continuing Medical Education; North American Center for Continuing Medical Education
Research Funding - Pfizer (Inst)
 
Anne M. Noonan
Consulting or Advisory Role - Eisai; Exelixis; Helsinn Healthcare; QED Therapeutics
 
Michael J. Cavnar
Honoraria - OncLive/MJH Life Sciences
Travel, Accommodations, Expenses - Covidien/Medtronic
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Array BioPharma; Bayer; Eisai; Incyte; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
Ibrahim Halil Sahin
No Relationships to Disclose
 
Carlos Hou Fai Chan
Research Funding - AngioDynamics; Checkmate Pharmaceuticals